Q2 2024 · 13F-HR
Vestal Point Capital, LPholdings as filed
Filed 2024-08-14 · accession 0001974915-24-000006
$1.34B
Reported value
60
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G50871105 | JAZZ | Jazz Pharmaceuticals PLC | $160.1M | 11.9% | 1,500,000 | Common | SOLE |
| 23282W605 | CYTK | Cytokinetics Inc | $112.4M | 8.38% | 2,075,000 | Common | SOLE |
| 04351P101 | ASNDUSD | Ascendis Pharma A/S | $102.3M | 7.63% | 750,000 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $74.0M | 5.52% | 1,800,000 | Common | SOLE |
| 379577208 | GMED | Globus Medical Inc | $61.6M | 4.60% | 900,000 | Common | SOLE |
| 457669307 | INSM | Insmed Inc | $50.3M | 3.75% | 750,000 | Common | SOLE |
| 07725L102 | ONC | BeiGene Ltd | $49.9M | 3.72% | 350,000 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $49.0M | 3.65% | 1,200,000 | Common | SOLE |
| 30063P105 | EXK | Exact Sciences Corp | $39.1M | 2.91% | 925,000 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $37.3M | 2.78% | 675,000 | Common | SOLE |
| N44445109 | IMTX | Immatics NV | $32.0M | 2.38% | 2,750,000 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $30.4M | 2.26% | 725,000 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $29.6M | 2.21% | 3,250,000 | Common | SOLE |
| 483497103 | KALV | KalVista Pharmaceuticals Inc | $27.1M | 2.02% | 2,300,000 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $26.2M | 1.95% | 6,490,000 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics Inc | $26.0M | 1.94% | 1,750,000 | Common | SOLE |
| 03828A101 | APLT | Applied Therapeutics Inc | $25.4M | 1.89% | 5,430,000 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $24.1M | 1.80% | 300,000 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc | $22.0M | 1.64% | 560,000 | Common | SOLE |
| 53635D202 | LQDA | Liquidia Corp | $22.0M | 1.64% | 1,830,000 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $21.7M | 1.62% | 3,600,000 | Common | SOLE |
| N90064101 | QURE | uniQure NV | $21.3M | 1.59% | 4,750,000 | Common | SOLE |
| 110122108 | BMY | Bristol-Myers Squibb Co | $20.8M | 1.55% | 500,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $20.5M | 1.53% | 525,000 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines Inc | $18.2M | 1.36% | 440,000 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals Inc | $17.2M | 1.28% | 1,250,000 | Common | SOLE |
| 45332Y109 | NARIUSD | Inari Medical Inc | $16.9M | 1.26% | 350,000 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics Inc | $15.5M | 1.16% | 600,000 | Common | SOLE |
| 83422E204 | SLDB | Solid Biosciences Inc | $15.1M | 1.13% | 2,665,000 | Common | SOLE |
| 52886X107 | LXEO | Lexeo Therapeutics Inc | $13.5M | 1.00% | 840,000 | Common | SOLE |
| 03753U106 | APLSUSD | Apellis Pharmaceuticals Inc | $12.9M | 0.96% | 335,000 | Common | SOLE |
| 45257U108 | IMNM | Immunome Inc | $12.1M | 0.90% | 1,000,000 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc | $11.6M | 0.87% | 500,000 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics Inc | $10.4M | 0.78% | 500,000 | Common | SOLE |
| 09203E105 | BDTX | Black Diamond Therapeutics Inc | $9.8M | 0.73% | 2,100,000 | Common | SOLE |
| 09075V102 | BNTX | BioNTech SE | $8.0M | 0.60% | 100,000 | Common | SOLE |
| 457730109 | INSP | Inspire Medical Systems Inc | $8.0M | 0.60% | 60,000 | Common | SOLE |
| 695127100 | PCRX | Pacira BioSciences Inc | $8.0M | 0.60% | 280,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $7.9M | 0.59% | 225,000 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $7.2M | 0.54% | 1,160,000 | Common | SOLE |
| 02157Q109 | ANRO | Alto Neuroscience Inc | $6.6M | 0.49% | 620,000 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics Inc | $6.6M | 0.49% | 2,000,000 | Common | SOLE |
| 019770106 | ALLO | Allogene Therapeutics Inc | $5.1M | 0.38% | 2,200,000 | Common | SOLE |
| 702712100 | — | Passage Bio Inc | $4.8M | 0.36% | 6,052,000 | Common | SOLE |
| 92915B106 | VYGR | Voyager Therapeutics Inc | $4.7M | 0.35% | 600,000 | Common | SOLE |
| 36315X101 | LKFT | Galapagos NV | $4.5M | 0.33% | 180,000 | Common | SOLE |
| 98985Y108 | ZYME | Zymeworks Inc | $3.7M | 0.28% | 440,000 | Common | SOLE |
| 75955J402 | RLMD | Relmada Therapeutics Inc | $3.6M | 0.27% | 1,200,000 | Common | SOLE |
| 556099109 | MGNX | MacroGenics Inc | $3.4M | 0.25% | 800,000 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics Inc | $3.3M | 0.25% | 890,000 | Common | SOLE |
| 92332V107 | VTYXUSD | Ventyx Biosciences Inc | $3.0M | 0.23% | 1,315,000 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $2.8M | 0.21% | 90,000 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics Inc | $2.4M | 0.18% | 500,000 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $2.4M | 0.18% | 300,000 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine Inc | $2.3M | 0.17% | 450,000 | Common | SOLE |
| 16934W106 | CMRXEUR | Chimerix Inc | $1.2M | 0.09% | 1,400,000 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics PLC | $1.2M | 0.09% | 1,500,000 | Common | SOLE |
| 046513206 | ATRA | Atara Biotherapeutics Inc | $952,000 | 0.07% | 112,000 | Common | SOLE |
| 75974E103 | — | Reneo Pharmaceuticals Inc | $822,950 | 0.06% | 545,000 | Common | SOLE |
| N62509109 | NAMS | Newamsterdam Pharma Co NV | $480,250 | 0.04% | 25,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.